|
|
|
|
|
|
Early |
Seftel et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab050 (Peer Reviewed) |
death/ICU, ↓83.9%, p=0.15 |
Prospective cohort of fluvoxamine for early treatment of COVID-19 |
| Retrospective 125 outpatients, 77 treated with fluvoxamine, showing lower death/ICU admission (0 of 77 vs. 2 of 48), lower hospitalization (0 of 77 vs. 6 of 48), and faster recovery with treatment. Note that 12 treatment patients were add.. |
|
Details
Source
PDF
Early treatment study
Early treatment study
|
| Seftel et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab050 (Peer Reviewed) |
| Prospective cohort of fluvoxamine for early treatment of COVID-19 |
Retrospective 125 outpatients, 77 treated with fluvoxamine, showing lower death/ICU admission (0 of 77 vs. 2 of 48), lower hospitalization (0 of 77 vs. 6 of 48), and faster recovery with treatment. Note that 12 treatment patients were added but are not reflected in the table in the paper (because the numbers had been previously published and the IRB did not allow updating the table).
![]()
risk of combined death/ICU, 83.9% lower, RR 0.16, p = 0.15, treatment 0 of 77 (0.0%), control 2 of 48 (4.2%), continuity correction due to zero event.
risk of hospitalization, 94.0% lower, RR 0.06, p = 0.003, treatment 0 of 77 (0.0%), control 6 of 48 (12.5%), continuity correction due to zero event.
risk of no recovery, 98.7% lower, RR 0.01, p < 0.001, treatment 0 of 77 (0.0%), control 29 of 48 (60.4%), continuity correction due to zero event.
|
|
Submit Corrections or Comments
|
|
Early |
Lenze et al., JAMA, doi:10.1001/jama.2020.22760 (Peer Reviewed) |
progression, ↓92.7%, p=0.009 |
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial |
| RCT 152 outpatients, 80 treated with fluvoxamine showing lower progression with treatment (0 of 80 versus 6 of 72 control). |
|
Details
Source
PDF
Early treatment study
Early treatment study
|
| Lenze et al., JAMA, doi:10.1001/jama.2020.22760 (Peer Reviewed) |
| Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial |
RCT 152 outpatients, 80 treated with fluvoxamine showing lower progression with treatment (0 of 80 versus 6 of 72 control).
![]()
risk of disease progression, 92.7% lower, RR 0.07, p = 0.009, treatment 0 of 80 (0.0%), control 6 of 72 (8.3%), continuity correction due to zero event, clinical deterioration over 15 days.
risk of hospitalization, 82.0% lower, RR 0.18, p = 0.009, treatment 1 of 80 (1.2%), control 5 of 72 (6.9%), COVID-19 hospitalization within 15 days, see supplemental appendix for details.
|
|
Submit Corrections or Comments
|
|
Late |
Hoertel et al., Molecular Psychiatry, doi:10.1038/s41380-021-01021-4 (Peer Reviewed) |
Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study |
| Retrospective 7,230 hospitalized COVID-19 patients in France, 345 receiving an antidepressant medication within 48 hours of admission. There was a significant association between antidepressant use and reduced risk of intubation or death .. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Hoertel et al., Molecular Psychiatry, doi:10.1038/s41380-021-01021-4 (Peer Reviewed) |
| Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study |
Retrospective 7,230 hospitalized COVID-19 patients in France, 345 receiving an antidepressant medication within 48 hours of admission. There was a significant association between antidepressant use and reduced risk of intubation or death (HR 0.56, p < 0.001). Fluvoxamine is not included because there was only one person taking it in this study.
![]()
|
|
Submit Corrections or Comments
|
